Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURE: Xeomin for Post-stroke Upper Limb Spasticity
NCT01392300Phase 3Completed
- Sponsor
- Merz
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in spasticity comparing Xeomin 400U with Placebo (2 arms). Primary endpoints: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern at 4 weeks and Investigator's Global Impression of Change at 4 weeks. Started Sep 2011; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01392300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392300.